MA43977A - Méthode de traitement de patients atteints de cancer souffrant d'insuffisance rénale grave - Google Patents

Méthode de traitement de patients atteints de cancer souffrant d'insuffisance rénale grave

Info

Publication number
MA43977A
MA43977A MA043977A MA43977A MA43977A MA 43977 A MA43977 A MA 43977A MA 043977 A MA043977 A MA 043977A MA 43977 A MA43977 A MA 43977A MA 43977 A MA43977 A MA 43977A
Authority
MA
Morocco
Prior art keywords
treatment
cancer patients
kidney failure
severe kidney
severe
Prior art date
Application number
MA043977A
Other languages
English (en)
Inventor
Kenichiro Yoshida
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59501005&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA43977(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA43977A publication Critical patent/MA43977A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
MA043977A 2016-02-05 2017-02-03 Méthode de traitement de patients atteints de cancer souffrant d'insuffisance rénale grave MA43977A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662291799P 2016-02-05 2016-02-05

Publications (1)

Publication Number Publication Date
MA43977A true MA43977A (fr) 2018-12-12

Family

ID=59501005

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043977A MA43977A (fr) 2016-02-05 2017-02-03 Méthode de traitement de patients atteints de cancer souffrant d'insuffisance rénale grave

Country Status (12)

Country Link
US (4) US10456399B2 (fr)
EP (1) EP3412295A4 (fr)
JP (3) JP6882205B2 (fr)
KR (2) KR102298144B1 (fr)
AU (1) AU2017215825B9 (fr)
MA (1) MA43977A (fr)
NZ (1) NZ745113A (fr)
RU (1) RU2727598C2 (fr)
TW (1) TWI791430B (fr)
UA (1) UA123403C2 (fr)
WO (1) WO2017135412A1 (fr)
ZA (1) ZA201805245B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ745113A (en) * 2016-02-05 2021-12-24 Taiho Pharmaceutical Co Ltd Method for treating cancer patients with severe renal impairment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE245631T1 (de) 1995-03-29 2003-08-15 Taiho Pharmaceutical Co Ltd Uracilderivate und diese enthaltende antitumoreffekt-verstärker sowie antitumormittel
US7799783B2 (en) * 2005-01-26 2010-09-21 Taiho Pharmaceutical Co., Ltd. Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
RU2394581C2 (ru) * 2005-01-26 2010-07-20 Тайхо Фармасьютикал Ко., Лтд. ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
SI2746404T1 (en) * 2011-08-16 2018-04-30 Taiho Pharmaceutical Co., Ltd. ANTITUM AND THERAPEUTIC EFFECTS OF THE FORMAL METHOD FOR PATIENTS WITH KRAS-MUTRIC COLORECTAL CANCER
ES2824400T3 (es) * 2013-03-27 2021-05-12 Taiho Pharmaceutical Co Ltd Agente antitumoral que incluye clorhidrato de irinotecán hidratado
JP6312660B2 (ja) 2013-05-17 2018-04-18 大鵬薬品工業株式会社 Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法
CN106333952A (zh) 2014-02-19 2017-01-18 齐鲁制药有限公司 一种胸苷磷酸化酶抑制剂的结晶形式及其制备方法
NZ745113A (en) * 2016-02-05 2021-12-24 Taiho Pharmaceutical Co Ltd Method for treating cancer patients with severe renal impairment

Also Published As

Publication number Publication date
US20210177850A1 (en) 2021-06-17
US10960004B2 (en) 2021-03-30
TW201728328A (zh) 2017-08-16
RU2018131573A3 (fr) 2020-03-05
TWI791430B (zh) 2023-02-11
JPWO2017135412A1 (ja) 2018-12-06
KR102412690B1 (ko) 2022-06-23
JP2023065622A (ja) 2023-05-12
NZ745113A (en) 2021-12-24
WO2017135412A1 (fr) 2017-08-10
EP3412295A1 (fr) 2018-12-12
US20200030329A1 (en) 2020-01-30
KR102298144B1 (ko) 2021-09-03
EP3412295A4 (fr) 2019-09-25
ZA201805245B (en) 2019-10-30
US20240148730A1 (en) 2024-05-09
RU2018131573A (ru) 2020-03-05
AU2017215825B9 (en) 2020-11-26
KR20180104744A (ko) 2018-09-21
JP6882205B2 (ja) 2021-06-02
AU2017215825A1 (en) 2018-08-23
US20180338976A1 (en) 2018-11-29
RU2727598C2 (ru) 2020-07-22
UA123403C2 (uk) 2021-03-31
AU2017215825B2 (en) 2020-09-10
KR20210111348A (ko) 2021-09-10
JP2021113228A (ja) 2021-08-05
US10456399B2 (en) 2019-10-29

Similar Documents

Publication Publication Date Title
MA49144A (fr) Polythérapies pour le traitement du cancer
MA46771A (fr) Méthode de traitement de tumeur immunothérapeutique
MA43374A (fr) Méthodes de traitement de tumeurs malignes
MA55694A (fr) Méthodes de conditionnement de patients pour la thérapie cellulaire t
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
MA52371A (fr) Méthodes de traitement d'infections dues aux coronaviridae
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3277842T3 (da) Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer
DK3474841T3 (da) Fremgangsmåder til behandling af ar+-brystkræft
DK3777855T3 (da) Fremgangsmåder til behandling af fibrotiske sygdomme
MA40498A (fr) Méthode de traitement de l'intoxication par organophosphates
MA41449A (fr) Polythérapies pour le traitement de cancers
MA46361A (fr) Traitement du cancer de la prostate
MA48637A (fr) Polythérapies pour le traitement du cancer
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
MA50409A (fr) Polythérapies pour le traitement du cancer
MA44612A (fr) Méthodes de traitement de cancers pédiatriques
MA45149A (fr) Méthodes de traitement de la maladie d'alzheimer
MA47408A (fr) Traitement du cancer
MA49059A (fr) Traitement des cancers positifs à her2
MA45780A (fr) Méthodes de traitement du cancer de la prostate
MA53903A (fr) Méthode de traitement de la myasthénie grave
EA201691887A1 (ru) Лечение внутрипеченочных холестатических заболеваний
MA45046A (fr) Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules